Daraxonrasib Challenges Second-Line Pancreatic Cancer Care
Episode Summary
Daraxonrasib showed promising survival in KRAS-mutant metastatic pancreatic cancer, but stronger randomized evidence is needed before replacing standard second-line chemotherapy.